Pulling SEC filings + quote and writing the call…
NVCR
NovoCure Ltd
Next earnings Jul 20, 2026 · consensus $-0.34 EPS, $176M rev
Last earnings +27.5% on 2026-04-30
$13.68
▼ -4.20%$14.28▼ -20.25%
over 1Y
L $10.03EODHDH $18.46
Earnings Dividend Split Congress buy Congress sellFilings colored by tone · hover for detail
Today-4.2%
1W-19.4%
1M-16.0%
3M+17.5%
YTD+8.8%
1Y-20.2%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 13 analysts
Buy
Revenue grew 8.3% YoY; but unprofitable (net margin -20.8%).
NovoCure Ltd shows $655M in FY2025 revenue (+8.3% YoY), a -20.8% net margin, and -40.0% ROE.
Sources: SEC EDGAR (CIK 0001645113, latest 10-Q filed 2026-04-30) · EODHD · as of 6/19/2026, 3:40:27 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.